Opinion

Should the Best Medical Therapy for Stable Coronary Artery Disease Obviate the Need for Elective Percutaneous Coronary Intervention (PCI)? Is it time to Constrict the (Elective) Stents?

Erdogan Aygar1*, Bertram Pitt2

1American Hospital, Section of Cardiology, Istanbul, Turkey
2Department of Medicine, Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, MI, USA 48109

*Address for Correspondence: Erdogan Aygar, American Hospital, Section of Cardiology, Guzelbahce sokak, No: 20, Nisantasi, 34365Istanbul, Turkey, Tel: +905-325-060-878; Fax: +902-123-112-343; ORCID ID: orcid.org/0000-0002-8222-2912;
E-mail: erdoganaygar@hotmail.com; erdoganaygar@amerikanhastanesi.com

Submitted: 09 January 2019; Approved: 22 January 2019; Published: 25 January 2019

Cite this article: Aygar E, Pitt B, Arbor MI. Should the Best Medical Therapy for Stable Coronary Artery Disease Obviate the Need for Elective Percutaneous Coronary Intervention (PCI)? Is it time to Constrict the (Elective) Stents? Int J Clin Cardiol Res. 2019;3(1): 003-005.

Copyright: © 2019 Aygar E, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ISSN: 2639-3786
ABSTRACT

Percutaneous Coronary Intervention [PCI] has been a revolutionary advance in cardiology, and many lives have been saved as a result of the widespread application of primary PCI. However, elective PCI has not yet been proven to save lives or reduce the risk of myocardial infarction. Despite this lack of evidence, elective PCI has been misused and in some cases, abused for nonmedical reasons.

The considerable cost of elective PCI can be reduced, and the resources could potentially be utilized for better public health outcomes. The following article intends to highlight the lack of evidence supporting the use of elective PCI, which is a problem not only in North America and Europe but also throughout the world.

Better regulation of the elective PCI procedure could reduce health care expenditures and divert resources to cardiovascular disease prevention.

INTRODUCTION

One of the most controversial issues in clinical cardiology is whether a cardiologist should initiate optimal medical therapy with follow-up for symptoms in patients with symptomatic but stable ischemic heart disease or subject them to elective Percutaneous Coronary Intervention [PCI] on top of optimal medical treatment [1-3]. There is, however, no controversy that primary PCI is a lifesaving procedure in the setting of acute coronary ischemia. The pathophysiology of chronic stable coronary ischemia is different from that of acute coronary ischemia. Therefore, one should not expect the same favorable result with the same treatment when dealing with a different disease process [3].

Primary PCI is lifesaving, but elective [nonacute] PCI is NOT!

Primary PCI for ST-segment elevation acute coronary syndromes is one of the major breakthroughs of the past 25 years and has replaced thrombolytic therapy as the method of choice for reperfusion [4]. Primary PCI achieves superior reperfusion and reduces mortality, reinfarction and intracranial bleeding more effectively than pharmacological reperfusion [4]. Primary PCI is also an effective treatment strategy for non-ST-segment elevation acute coronary syndromes, reducing mortality, reinfarction and duration of hospital stay [5]. However, extrapolation of the success of primary PCI to elective PCI might not be justified [1, 3,6,7].

Does elective PCI provide effective and sustained angina relief?

Relief of the symptoms of angina pectoris has been shown to be more rapid with elective PCI than with optimal medical treatment alone in the COURAGE trial [8]. However, this symptomatic benefit does not persist and becomes nonsignificant at 6 months [9]. Furthermore, this "temporary superiority" of elective PCI for angina relief was achieved with the help of multiple antianginal medications. Even after a successful PCI, interventionists use triple anti-anginal therapy almost as often as in the medical treatment arm, making it difficult to determine whether the resolution of angina was due to relief of the coronary obstruction or addition of the anti-anginal medications. Approximately 85% of PCI patients were still on a beta-blocker, and more than 45% were on calcium antagonists and/or nitrates despite a good angiographic result [8].

The ORBITA trial recently raised the possibility that the angina-relieving effect of elective PCI may in a large part be a placebo effect [10]. In this trial, patients with severe coronary stenosis and stable angina pectoris were randomized into either a true-PCI or sham-PCI arm. There were no differences between the groups in either angina resolution or treadmill time [10].

Should we be treating coronary ischemia or should we be treating coronary atheromas?

For many decades, cardiologists have thought that chronic coronary ischemia was associated with poor clinical outcomes and the resolution of ischemia with good outcomes. This "ischemia dogma" had never been challenged until the publication of the STICH [Surgical Treatment for IsChemic Heart Failure] study [11]. The presence of ischemia at baseline did not predict which patient was to benefit from revascularization, and the prognosis of the patients did not differ by the presence or absence of baseline ischemia. Some authors began to challenge the "dogma" of ischemia by asking "Is ischemia dead after STICH?" [12], some asked "Should ischemia guide revascularization?" [13], and some even asked "Is ischemia truly bad for you?", implying that ischemia in and of itself may not be bad but it might be a surrogate marker for coronary plaque burden [14].

A more modern and specific way of detecting coronary ischemia, Fractional Flow Reserve [FFR]-guided treatment strategies, has been tested in a prospective randomized trial, i.e., the FAME-2 trial [15]. This trial failed to show any prevention of hard events when elective PCI was guided by the FFR technique. The claimed benefit of the FFR-guided but unblinded elective PCI procedures on the prevention of urgent revascularizations has therefore remained questionable [16,17].

The growing skepticism about the relief of chronic coronary ischemia set the stage for the ISCHEMIA trial [NCT01471522], which has completed enrollment. This trial may help us to understand whether the resolution of ischemia with an elective PCI will provide an incremental clinical benefit over intensive medical treatment targeted to modify and stabilize coronary atheromas.

Why, then, are we still doing elective [nonacute] PCI?

Despite all the clinical trials and preponderance of literature suggesting that “… elective PCI does not reduce the risk of future MI or death, and does not provide sustained angina relief…” [7, 8], what might be the potential reasons for the persistence of elective PCI procedures in daily practice? Some of the “nonvisible” triggers for elective PCI procedures include misperception-based patient requests, peer pressure and global economic/consumerist pressures [18,19].

CONCLUSION

The number of elective PCI cases has declined since 2006, coinciding with the publication of the COURAGE and BARI-2D trials [6]. Despite this evidence, approximately 500,000 patients undergo elective PCI procedures every year for symptomatic relief of stable angina in the USA and Europe [20]. The clinical benefit of these...
procedures is arguable at best and procedure-related complications, including per procedural [and long-term] death, stroke, and kidney injury have reached a level that may have major public health implications [20]. A “restricted” use of elective PCI might allow us to avoid these unneeded iatrogenic complications and “redirect” some of our resources from “Elective PCI Centers” to community-based “Preventive Cardiology Centers”.

The ongoing ISCHEMIA trial [NCT 01471522], the results of which should be available by the end of 2019, is the largest comparative effectiveness trial in patients with stable ischemic heart disease. This trial has completed the enrollment of 5179 patients with stable ischemic heart disease, moderate-to-severe ischemia on a perfusion scan and angiographic evidence of significant coronary stenosis. Patients were randomized into either an optimal medical therapy-only arm or optimal medical therapy plus an elective PCI arm. The end points are all-cause mortality, myocardial infarction, stroke, new heart failure and kidney injury as well as quality of life. With the combined data from the ORBITA [10] and ISCHEMIA [NCT 01471522] trials, we may need to reconsider the rules for elective PCI. Until the results of the ISCHEMIA trial are available, however, it would be prudent to institute and evaluate the effects of optimal medical therapy before considering elective PCI for patients with chronic angina pectoris.

REFERENCES